I agree with your description that the two drugs are coadministered. I do not think that means that it is a “maturation agent” in this context. I think that is back to the notion that it’s one drug. I do agree that it makes sense for the company to find a way, as soon as possible, to work with Oncovir to ensure that patients, going forward, not just in trials, can access and have Poly-ICLC, specifically Hiltonol, with their DCVax-L injections, as an adjuvant treatment that stimulates the immune system broadly, not just the dendritic cells in the vaccine. It does so by pretending to be viral DNA. It would be good if the companies find ways to collaborate, work together and commercialize in a manner that provides patients with the best possible solution, as well as positions both companies to prosper from the collaboration.
Bullish
News 
Market Data 
Discover 
